Wonbiogen Valuation
Is A307280 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A307280 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A307280 (₩1234) is trading below our estimate of fair value (₩6292.59)
Significantly Below Fair Value: A307280 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A307280?
Key metric: As A307280 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is A307280's PE Ratio? | |
|---|---|
| PE Ratio | 8.1x |
| Earnings | ₩5.39b |
| Market Cap | ₩43.45b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 4.4x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does A307280's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 24x | ||
A263690 DRGEM | 10.8x | n/a | ₩64.9b |
A122310 Genoray | 10.1x | n/a | ₩76.7b |
A261200 DENTISLtd | 68.3x | n/a | ₩93.8b |
A065510 Huvitz | 6.9x | n/a | ₩84.1b |
A307280 Wonbiogen | 8.1x | n/a | ₩43.5b |
Price-To-Earnings vs Peers: A307280 is good value based on its Price-To-Earnings Ratio (8.1x) compared to the peer average (24x).
Price to Earnings Ratio vs Industry
How does A307280's PE Ratio compare vs other companies in the KR Medical Equipment Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
A035610 Solborn | 2.6x | n/a | US$69.19m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: A307280 is good value based on its Price-To-Earnings Ratio (8.1x) compared to the KR Medical Equipment industry average (12.1x).
Price to Earnings Ratio vs Fair Ratio
What is A307280's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 8.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A307280's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Access Bio
₩188.3b
Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
A950130
₩5,780.00
7D
2.1%
1Y
-34.0%
Boditech Med
₩346.3b
Offers instruments and diagnostic reagents in South Korea and internationally.
A206640
₩15,090.00
7D
-7.2%
1Y
-17.6%
Sewoon Medical
₩110.6b
Engages in the research and development, manufacture, and sale of medical products in South Korea.
A100700
₩2,560.00
7D
-1.7%
1Y
-9.1%